| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $759,944 ) |
| | 2025 | 2025 | NEXTGENJANE INC | 400 29TH ST | OAKLAND | CA | 94609-3546 | ALAMEDA | USA | R44HD118899 | Performance evaluation of a non-invasive menstrual test for endometriosis in infertility patients | 000 | 1 | NIH | 4/15/2025 | $759,944 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2023 | NEXTGENJANE INC | 400 29TH ST | OAKLAND | CA | 94609-3546 | ALAMEDA | USA | R44HD103159 | Developing a non-invasive, definitive diagnostic for endometriosis using biomarkers in menstrual effluence | 000 | 3 | NIH | 8/23/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $401,530 ) |
| | 2023 | 2023 | NEXTGEN JANE, INC. | 400 29TH ST STE 105 | OAKLAND | CA | 94609-3546 | ALAMEDA | USA | R44HD103159 | Developing a non-invasive, definitive diagnostic for endometriosis using biomarkers in menstrual effluence | 000 | 3 | NIH | 1/25/2023 | $401,530 |
|
| Issue Date FY: 2022 ( Subtotal = $1,108,476 ) |
| | 2022 | 2022 | NEXTGEN JANE, INC. | 400 29TH ST STE 105 | OAKLAND | CA | 94609-3546 | ALAMEDA | USA | R44HD103159 | Developing a non-invasive, definitive diagnostic for endometriosis using biomarkers in menstrual effluence | 001 | 2 | NIH | 2/8/2022 | $1,108,476 |
| | 2022 | 2020 | NEXTGEN JANE, INC. | 400 29TH ST STE 105 | OAKLAND | CA | 94609-3546 | ALAMEDA | USA | R44HD103159 | Developing a non-invasive, definitive diagnostic for endometriosis using biomarkers in menstrual effluence | 000 | 1 | NIH | 2/8/2022 | $0 |
| | 2022 | 2020 | NEXTGEN JANE, INC. | 400 29TH ST STE 105 | OAKLAND | CA | 94609-3546 | ALAMEDA | USA | R44HD103159 | Developing a non-invasive, definitive diagnostic for endometriosis using biomarkers in menstrual effluence | 002 | 1 | NIH | 6/1/2022 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $267,669 ) |
| | 2020 | 2020 | NEXTGEN JANE, INC. | 400 29TH ST STE 105 | OAKLAND | CA | 94609-3546 | ALAMEDA | USA | R44HD103159 | Developing a non-invasive, definitive diagnostic for endometriosis using biomarkers in menstrual effluence | 000 | 1 | NIH | 8/21/2020 | $227,426 |
| | 2020 | 2020 | NEXTGEN JANE, INC. | 400 29TH ST STE 105 | OAKLAND | CA | 94609-3546 | ALAMEDA | USA | R44HD103159 | Developing a non-invasive, definitive diagnostic for endometriosis using biomarkers in menstrual effluence | 001 | 1 | NIH | 9/25/2020 | $40,243 |
|
|
